Comparative Analysis of MBNL1 Antibodies: Characterization of Recognition Sites and Detection of RNA Foci Colocalization.

Yoshitaka Aoki, Ai Ohki, Motoaki Yanaizu, Yoshihiro Kino

Abstract readComparative Study

In one paragraph

Article in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Functional sQTLs regulating PTK2B exon 31 splicing uncover an RNA-dependent modulation of its kinase activity and cellular phenotype.Cell communication and signaling : CCS · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yoshitaka AokiDepartment of RNA Pathobiology and Therapeutics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-shi 204-8588, Tokyo, Japan.

Ai OhkiDepartment of RNA Pathobiology and Therapeutics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-shi 204-8588, Tokyo, Japan.

Motoaki YanaizuDepartment of RNA Pathobiology and Therapeutics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-shi 204-8588, Tokyo, Japan.

Yoshihiro KinoDepartment of RNA Pathobiology and Therapeutics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-shi 204-8588, Tokyo, Japan.ORCID 0000-0003-0862-8065

Funding

Ministry of Education, Culture, Sports, Science and Technology 19J15024Ministry of Education, Culture, Sports, Science and Technology 21K20700Ministry of Education, Culture, Sports, Science and Technology 22K07525Ministry of Education, Culture, Sports, Science and Technology 25K10779

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AntibodiesMyotonic DystrophyRNARNA-Binding ProteinsExonsHEK293 CellsHumansImmunoprecipitationIn Situ Hybridization, FluorescenceProtein IsoformsAntibodiesMBNL1 protein, humanProtein IsoformsRNARNA-Binding ProteinsantibodyMBNL1myotonic dystrophyRNA foci

Identifiers

PMID40565550

DOI10.3390/genes16060658

PMCPMC12192522

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.